Practicing on 3D-printed models cuts surgery time, costs

Practicing before a surgery, especially for procedures on children, helps reduce surgery time and costs. In a study published in the Journal of Children's Orthopaedics, engineers and pediatric orthopedic surgeons have utilized 3D printing to help surgeons train for a common hip disorder in children 9 to 16 that cuts surgery times by 25 percent.

A team of bioengineers from the University of California, San Diego and physicians from Rady Children's Hospital was led by Vidyadhar Upasani, a pediatric orthopedic surgeon and senior author on the study, used 3D prints of a pelvis from CT scans to mimic the structure encountered during surgery. Using a honeycomb structure to mimic the feeling of bone, the 3D commercial printer was able to print a model in 10 hours.

Slipped capital femoral epiphysis, which affects 11 of every 100,000 children, occurs when a patient’s femur is deformed after it slips along the growth plate. The study enrolled 10 patients, five of whom underwent surgery without their surgeons practicing on a model and five procedures where the surgeons practiced beforehand.

Results showed that the surgeries where the surgeon practiced on the model beforehand were 28 to 45 minutes shorter than the control. This time saved resulted in a savings of $2,700 per surgery.

"Being able to practice on these 3D models is crucial," said Upasani. "I've seen how beneficial 3D models are. It's now hard to plan surgeries without them."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.